sequenom laboratories announces electropositive results from clinical establishment work on the maternit genome quiz – chawbacon finance
* Fractions of perceptible chromosomal and subchromosomal abnormalities were derived from the specifications of the MaterniT GENOME quiz and otc wide ill-used non-invasive antenatal tests, conjugate with preponderance data as authenticated in [Norton ME, et al. Am J Obstet Gynecol. EPub two 1000 15 Dec 18] and [Wellesley D., et al. Eur J Hum Genet. EPub two chiliad dozen Jan 11]
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular nosology lab, has highly-developed a unsubtle ambit of lab tests, with a centering chiefly on antepartum aid. Branded nether the names HerediT®, MaterniT®, NextView®, SensiGene® and VisibiliT™, these molecular inherited laboratory-developed tests allow former patient direction entropy for obstetricians, geneticists, and paternal foetal music specialists. Sequenom Laboratories is ever-changing the landscape in transmissible nosology exploitation proprietorship forefront technologies. Inflict www.laboratories.sequenom.com and espouse @SequenomLabs.
“The MaterniT GENOME exam has been extensively validated, both analytically and clinically,” aforesaid Dr. van den Bunce. “In add-on to providing physicians and patients the virtually comp data from any NIPT useable nowadays, the MaterniT GENOME trial demonstrates Sequenom Laboratories’ dedication to leaders in the NIPT market and women’s wellness.”
Therein cogitation, the MaterniT GENOME tryout showed:
The results published in this clinical study reflect the diligent effort, expertise and scientific process that went into validating the MaterniT GENOME test.”The study compared the MaterniT GENOME test results for 1,166 clinical samples with results from analysis of invasively-obtained amniocentesis or chorionic villus sampling (CVS) material. It included one hundred fifty one samples with common aneuploidies (trisomies 21, 18, and thirteen and sex chromosome aneuploidies), as well as eight rare aneuploidies and thirty five subchromosomal abnormalities distributed across the genome. The study demonstrated that the MaterniT GENOME test was able to detect changes in copy number for full chromosomes, as well as subchromosomal copy number changes as small as seven megabases—a resolution comparable to traditional cytogenetic karyotyping.Sequenom, Inc. (SQNM) is a pioneering genetic testing company dedicated to women’s health through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information. For more information, visit www.sequenom.com.
The sketch may now be downloaded at: http://www.ajog.org/article/S0002-9378(16)00318-5/pdf“The power to
You let poised a marvellous categorisation of try essays essaywritingservicez.tk Whether a writer is trying to convince you of something but fails to do so, in your ruling, your decisive personal response can be rattling illuminating. Pin to that primary composition throughout the essay
non-invasively find chromosomal and subchromosomal abnormalities crosswise the genome is decisive in clinical practise; abnormalities bey the major trisomies (21, 18, and 13) and sex chromosome aneuploidies constitute more 20% of all karyotype-level abnormalities in the world-wide obstetrical universe,” aforesaid Dr. van den Bonanza. “The MaterniT GENOME examination was intentional to nosepiece this data gap, and our clinical lab feel to appointment with complete 6,000 MaterniT GENOME tests has in fact shown that about 25% of samples with unnatural results had rarefied abnormalities crossways the total genome that would get been insensible by over-the-counter cfDNA examination methods.*”SAN DIEGO, Feb. 25, two g 16 /PRNewswire/ — Sequenom, Inc., (SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the publication of a clinical validation study on the MaterniT® GENOME laboratory-developed test in the American Journal of Obstetrics and Gynecology.The study, titled Clinical Validation of a Non-Invasive Prenatal Test for Genome-Wide Detection of Fetal Copy Number Variants (Lefkowitz, et al.), demonstrated high resolution, sensitive and specific detection of a wide range of sub-chromosomal and whole chromosomal abnormalities that were previously only detectable by karyotype analysis of invasively obtained samples. In some instances, genome-wide noninvasive prenatal testing (NIPT) also provided additional clarification about the origin of genetic material that had not been elucidated by karyotype analysis.”In 2011, Sequenom Laboratories pioneered cell-free DNA prenatal testing with the first laboratory-developed NIPT for trisomy 21, and we continued to innovate by adding content, such as other aneuploidies and select microdeletions,” said Dirk van den Boom, PhD, President and CEO of Sequenom. “In 2015, we further evolved NIPT with the first genome-wide test, MaterniT GENOME.